On January 31st and February 1st, the Reagan-Udall Foundation for the Food and Drug Administration 1 hosted a virtual event, Advancing Psychedelic Clinical Study Design. Using the FDA’s draft guidance for industry—Psychedelic Drugs: Considerations for Clinical Investigations—as a jumping-off point, the meeting saw discussion of a variety of topics: from handling issues like blinding and controls…
